PRESS RELEASE
April 27, 2018
Saniona, a leading biotech company in the field of ion channels, today announces that the English version of the Annual report for 2017 is now available on the company's website www.saniona.com.
For more information, please contact
Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: tf@saniona.com
The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEDT on April 27, 2018.
About Saniona
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, BenevolentAI, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq Stockholm Small Cap and has about 5,300 shareholders. The company's share is traded under the ticker SANION. Read more at www.saniona.com.
Attachments
- 20180427 - PR - Annual report - UK (https://prlibrary-eu.nasdaq.com/Resource/Download/d0d9c956-d7c6-4ebe-a7ea-cee75e2c804a)
- 20180427 Saniona Annual Report 2017 - UK (https://prlibrary-eu.nasdaq.com/Resource/Download/8a12e2a6-8319-49b4-85b0-c58f7e7465ec)
